Health Condition 1: L709- Acne, unspecified
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Male and female volunteers, with age 18â??45 years 2. Subjects willing and able to provide informed consent voluntarily 3. Subjects with facial acne grade of I-III as assessed by Investigatorâ??s Global Assessment 4. Willing to maintain the investigational product use throughout the study. 5. Subjects who have not undergone any skin therapy in last 3 months 6. Subjects with no known allergy to any of the test ingredients 7. Women using oral contraceptives must have been doing so for at least 6 consecutive months prior to entering the study, and are required to continue with the same brand throughout the study period 8. Subjects who are willing to refrain from using any skin care product other than the investigational product, like, moisturizers, face washes and face creams, for the duration of the study 9. Subjects willing and able to comply with all trial requirements 10. Laboratory workup within normal limits; including complete hemogram, glucose, blood urea nitrogen, creatinine, liver function test, lipid profile, thyroid-stimulating hormone, urine pregnancy test
Exclusion criteria
Exclusion criteria: 1. Subjects who have skin diseases like psoriasis, atopic dermatitis etc. at the time of screening 2. Subject with chronic systemic illnesses or treatment that can affect skin health eg. Polycystic ovarian disease 3. Subjects on oral medications or suffering from chronic illness which will compromise the study 4. Women who have stopped using oral contraceptives less than three months prior to entering the study 5. Subjects who have participated in a similar investigation in the past four weeks 6. Pregnant or lactating women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in the distribution of lesions as assessed by the IGA and GAG scale at 4 weeks and 8 weeksTimepoint: at 30th and 60th day of the trial | — |
Secondary
| Measure | Time frame |
|---|---|
| The subject/subject guardian will be asked to evaluate the treatment outcome on a 7-point scale as, evaluated on a 7-point scale: Changes in oiliness (snigdhata), erythema (saraktata), itching (kandu) and burning sensation (daha) will be measuredTimepoint: at 30th and 60th day of trial | — |
Countries
India
Contacts
A nit of Gokula Education Foundation